When you linking your Twitter Account Market Wire News Trending Stocks news and your Portfolio Stocks News will automatically tweet from your Twitter account.
Be alerted of any news about your stocks and see what other stocks are trending.
PRVL - Prevail's IND for PR001 for neuronopathic gaucher disease is now active
Prevail Therapeutics Inc.
The FDA has notified Prevail Therapeutics (NASDAQ:PRVL) that its Investigational New Drug (IND) application for PR001 for the treatment of neuronopathic Gaucher disease (nGD) patients is now active and that Prevail may proceed with initiating its proposed clinical trial.
More news on: Prevail Therapeutics Inc., Healthcare stocks news,